Serum levels of FGF-21 are increased in coronary heart disease patients and are independently associated with adverse lipid profile

• Published in: PloS one 2010-12, Vol.5 (12), p.e15534-e15534
• Main Authors: Lin, Zhuofeng, Wu, Zhen, Yin, Xiaojing, Liu, Yanlong, Yan, Xinxin, Lin, Shaoqiang, Xiao, Jian, Wang, Xiaojie, Feng, Wenke, Li, Xiaokun
• Format: Article
• Language: English
• Subjects: Aged; Analysis; Animal models; Anthropometry - methods; Apolipoproteins; Bethune, Norman (1890-1939); Biology; Blood; Blood cholesterol; Blood glucose; Body mass; C-reactive protein; Cardiac patients; Cardiovascular disease; Cardiovascular diseases; Case-Control Studies; Cholesterol; Coronary artery disease; Coronary Disease - blood; Coronary Disease - metabolism; Coronary heart disease; Correlation analysis; Diabetes mellitus; Diabetics; Endocrinology; Fasting; Female; Fibroblast growth factors; Fibroblast Growth Factors - blood; Glucose; Glucose - metabolism; Heart diseases; High density lipoprotein; Homeostasis; Humans; Hypertension; Insulin; Insulin Resistance; Lipid Metabolism; Lipids - blood; Low density lipoprotein; Low density lipoproteins; Male; Medical research; Medicine; Metabolism; Middle Aged; Obesity; Patients; Physiological aspects; Plasma levels; Proteins; Regression Analysis; Rodents; Serum levels; Triglycerides; Triglycerides - metabolism; Type 2 diabetes
• ISSN: 1932-6203; 1932-6203
• DOI: 10.1371/journal.pone.0015534

Fibroblast growth factor 21 (FGF-21) is a metabolic regulator with multiple beneficial effects on glucose homeostasis and lipid metabolism in animal models. The relationship between plasma levels of FGF-21 and coronary heart disease (CHD) in unknown. This study aimed to investigate the correlation of serum FGF-21 levels and lipid metabolism in the patients with coronary heart disease. We performed a logistic regression analysis of the relation between serum levels of FGF-21 and CHD patients with and without diabetes and hypertension. This study was conducted in the Departments of Endocrinology and Cardiovascular Diseases at two University Hospitals. Participants consisted of one hundred and thirty-five patients who have been diagnosed to have CHD and sixty-one control subjects. Serum FGF-21 level and levels of fasting blood glucose; triglyceride; apolipoprotein B100; HOMA-IR; insulin; total cholesterol; HDL-cholesterol; LDL-cholesterol; and C-reactive protein were measured. We found that median serum FGF-21 levels were significantly higher in CHD than that of control subjects (P